{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:36:16Z","timestamp":1792506976425,"version":"4.5.0"},"reference-count":22,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"vor","delay-in-days":66,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To evaluate efficacy and safety of LixiLan (iGlarLixi), a novel titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both components, iGlar and Lixi, given separately in type 2 diabetes inadequately controlled on metformin with or without a second oral glucose-lowering drug.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>After a 4-week run-in to optimize metformin and stop other oral antidiabetic drugs, participants (N = 1,170, mean diabetes duration \u223c8.8 years, BMI \u223c31.7 kg\/m2) were randomly assigned to open-label once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose &amp;lt;100 mg\/dL (&amp;lt;5.6 mmol\/L) up to a maximum insulin dose of 60 units\/day, or to once-daily Lixi (20 \u03bcg\/day) while continuing with metformin. The primary outcome was HbA1c change at 30 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Greater reductions in HbA1c from baseline (8.1% [65 mmol\/mol]) were achieved with iGlarLixi compared with iGlar and Lixi (\u22121.6%, \u22121.3%, \u22120.9%, respectively), reaching mean final HbA1c levels of 6.5% (48 mmol\/mol) for iGlarLixi versus 6.8% (51 mmol\/mol) and 7.3% (56 mmol\/mol) for iGlar and Lixi, respectively (both P &amp;lt; 0.0001). More subjects reached target HbA1c &amp;lt;7% with iGlarLixi (74%) versus iGlar (59%) or Lixi (33%) (P &amp;lt; 0.0001 for all). Mean body weight decreased with iGlarLixi (\u22120.3 kg) and Lixi (\u22122.3 kg) and increased with iGlar (+1.1 kg, difference 1.4 kg, P &amp;lt; 0.0001). Documented symptomatic hypoglycemia (\u226470 mg\/dL) was similar with iGlarLixi and iGlar (1.4 and 1.2 events\/patient-year) and lower with Lixi (0.3 events\/patient-year). iGlarLixi improved postprandial glycemic control versus iGlar and demonstrated considerably fewer nausea (9.6%) and vomiting (3.2%) events than Lixi (24% and 6.4%, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>iGlarLixi complemented iGlar and Lixi effects to achieve meaningful HbA1c reductions, close to near normoglycemia without increases in either hypoglycemia or weight, compared with iGlar, and had low gastrointestinal adverse effects compared with Lixi.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc16-0917","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T22:07:14Z","timestamp":1471385234000},"page":"2026-2035","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":257,"title":["Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial"],"prefix":"10.2337","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct02058147","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01336023","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02058147","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Julio","family":"Rosenstock","sequence":"first","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Aronson","sequence":"additional","affiliation":[{"name":"LMC Diabetes & Endocrinology, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grunberger","sequence":"additional","affiliation":[{"name":"Grunberger Diabetes Institute, Bloomfield Hills, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markolf","family":"Hanefeld","sequence":"additional","affiliation":[{"name":"GWT-TUD GmbH, Dresden Technical University, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PierMarco","family":"Piatti","sequence":"additional","affiliation":[{"name":"San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Serusclat","sequence":"additional","affiliation":[{"name":"Groupe Hospitalier Mutualiste Les Portes du Sud, V\u00e9nissieux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Cheng","sequence":"additional","affiliation":[{"name":"Sanofi R&D, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyue","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Niemoeller","sequence":"additional","affiliation":[{"name":"Diabetes Division, Sanofi, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Souhami","sequence":"additional","affiliation":[{"name":"Diabetes Division, Sanofi, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Davies","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester, Leicester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the LixiLan-O Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2016,8,15]]},"reference":[{"key":"2022031301072901600_B1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301072901600_B2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/dmrr.733","article-title":"When basal insulin therapy in type 2 diabetes mellitus is not enough\u2014what next","volume":"23","author":"Raccah","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031301072901600_B3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jdiacomp.2014.07.007","article-title":"Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis","volume":"28","author":"Charbonnel","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2022031301072901600_B4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00125-006-0203-x","article-title":"Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus","volume":"49","author":"Bonora","year":"2006","journal-title":"Diabetologia"},{"key":"2022031301072901600_B5","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/diacare.24.10.1734","article-title":"Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes","volume":"24","author":"Erlinger","year":"2001","journal-title":"Diabetes Care"},{"key":"2022031301072901600_B6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2337\/dc06-1612","article-title":"The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes","volume":"30","author":"Monnier","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031301072901600_B7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13300-015-0127-x","article-title":"Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists","volume":"6","author":"Uccellatore","year":"2015","journal-title":"Diabetes Ther"},{"key":"2022031301072901600_B8","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.ijo.0802173","article-title":"When oral agents fail: practical barriers to starting insulin","volume":"26","author":"Korytkowski","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2022031301072901600_B9","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/0145721705285638","article-title":"Dispelling myths and removing barriers about insulin in type 2 diabetes","volume":"32","author":"Meece","year":"2006","journal-title":"Diabetes Educ"},{"key":"2022031301072901600_B10","first-page":"A297","article-title":"Reasons for discontinuation of GLP-1 receptor antagonists: data from a large cross-sectional survey of physicians and type 2 diabetic patients","volume":"64","author":"Sikirica","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301072901600_B11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2337\/dc14-1984","article-title":"Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial","volume":"38","author":"Meier","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301072901600_B12","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutniak","year":"1992","journal-title":"N Engl J Med"},{"key":"2022031301072901600_B13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdiacomp.2013.10.003","article-title":"Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials","volume":"28","author":"Raccah","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2022031301072901600_B14","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031301072901600_B15","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031301072901600_B16","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","article-title":"Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031301072901600_B17","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2337\/dc16-0046","article-title":"Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031301072901600_B18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.diabres.2014.08.003","article-title":"Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials","volume":"106","author":"Owens","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031301072901600_B19","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031301072901600_B20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study","volume":"49","author":"Yki-J\u00e4rvinen","year":"2006","journal-title":"Diabetologia"},{"key":"2022031301072901600_B21","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2337\/dc16-0014","article-title":"Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031301072901600_B22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","article-title":"Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes Endocrinol"}],"updated-by":[{"DOI":"10.2337\/dc17-er06c","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000}}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc16-0917","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/11\/2026\/544198\/dc160917.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/11\/2026\/544198\/dc160917.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T04:44:50Z","timestamp":1647146690000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/11\/2026\/37228\/Benefits-of-LixiLan-a-Titratable-Fixed-Ratio"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,15]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,8,15]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-0917","relation":{"correction":[{"id-type":"doi","id":"10.2337\/dc17-er06c","asserted-by":"object"}]},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,15]]}}}